Drug Topics March 25, 2025
Lydia Newsom, PharmD, discusses how to support patients who are struggling with injection techniques or gastrointestinal side effects of GLP-1s.
In the United States, data from the CDC shows that over 40% of adults have obesity and 9.7% have severe obesity.1 Obesity, which is a chronic condition, increases the risk of several disease states, including hypertension, type 2 diabetes (T2D), coronary heart disease, stroke, and some cancers.
Glucagon-like peptide-1 (GLP-1) receptor agonists, which were originally approved to treat T2D, have shown significant efficacy in treating overweight and obesity and have become increasingly popular. According to a poll from KFF, 1 in 5 patients said they took GLP-1s for weight loss.2 However, side effects of GLP-1s can include gastrointestinal issues such...
Today's Sponsors
Today's Sponsor